(Q37461474)

20 August 2017

1 reference

title

Pharmacogenetics of vitamin K antagonists: useful or hype? (English)

1 reference

20 August 2017

0 references

0 references

1 reference

3

Emmanuel J Favaloro

1 reference

20 August 2017

1

Giuseppe Lippi

1 reference

20 August 2017

2

Massimo Franchini

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Clinical Chemistry and Laboratory Medicine

20 August 2017

published in

1 reference

20 August 2017

volume

47

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

503-515

1 reference

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Clinical pharmacogenetics and potential application in personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Pharmacogenomics of Drugs Affecting the Cardiovascular System

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

The story of the discovery of heparin and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Evaluation of genetic factors for warfarin dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Association between the CYP2C9 polymorphism and the drug metabolism phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Azathioprine-induced warfarin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Developing a sustainable process to provide quality control materials for genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Medical applications of haplotype-based SNP maps: learning to walk before we run.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Genetic testing for warfarin dosing? Not yet ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Genetic testing for warfarin therapy initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Incremental parameter evaluation from incomplete data with application to the population pharmacology of anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Diagnostic issues in thrombophilia: a laboratory scientist's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Research translation: a new frontier for clinical laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

A genotyping method for VKORC1 1173C > T by Pyrosequencing technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Survival of heparins, oral anticoagulants, and aspirin after the year 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

Will "personalized medicine" need personalized laboratory approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2009.140

21 January 2018

Identifiers

DOI

10.1515/CCLM.2009.140

1 reference

20 August 2017

1 reference